Paper Details

  1. Home
  2. Paper Details

Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients.

Author: ChenXi, GaoJinjin, HeJianmei, HuangJianwen, JiangYang, JiangYonglin, LiangMengran, ZhengJun, ZouXiaobai

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study aims to determine if efforts to prevent pneumococcal pneumonia are still worthwhile, particularly in HIV-infected patients in China. Currently, the vaccination rate for the 23-valent pneumococcal polysaccharide vaccine (PPV23) among this population is low due to limited understanding of its protective effects and safety. The study will provide data to inform government policy regarding designated vaccination programs for HIV-infected persons.
Paper Details　
Original Abstract of the Article :
Due to the lack of understanding of the protective effects and safety of 23-valent pneumococcal polysaccharide vaccine (PPV23) in immune-deficient populations, the vaccination rate of PPV23 among HIV-infected patients is still very low in China. The main objectives of this study were to determine wh...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2021.11.058

データ提供：米国国立医学図書館（NLM）

23-Valent Pneumococcal Capsular Polysaccharide Vaccine: Navigating the Desert of HIV-Related Infections

The fight against pneumococcal infections in HIV-infected individuals poses a unique challenge in the field of infectious diseases. This study focuses on the effectiveness and safety of the 23-valent pneumococcal capsular polysaccharide vaccine (PPV23) in this vulnerable population. Researchers explored the impact of PPV23 on preventing pneumococcal pneumonia and analyzed the cost-benefit ratio of vaccination in HIV-infected patients. The study’s findings aim to inform vaccination strategies for HIV-infected individuals and provide evidence-based guidance for government policy.

Protecting Vulnerable Populations: A Journey Through the Desert of HIV-Related Infections

The study underscores the importance of providing effective preventive measures for HIV-infected individuals, who are at increased risk of serious bacterial infections. The findings provide valuable insights into the potential benefits of PPV23 in this population, highlighting its role in reducing the incidence of pneumococcal pneumonia. This study serves as a reminder of the ongoing need to develop and implement effective vaccination strategies to protect vulnerable populations.

A Shield Against Infection: Navigating the Desert with Protection

The study highlights the critical role of vaccination in protecting individuals with compromised immune systems. It emphasizes the importance of understanding the effectiveness and safety of vaccines in different populations, ensuring that optimal strategies are implemented to prevent infectious diseases. This research reinforces the importance of public health initiatives aimed at promoting vaccination and ensuring the well-being of all individuals, especially those most vulnerable to infections.

Dr.Camel's Conclusion

This study explores the importance of vaccination in protecting HIV-infected individuals from pneumococcal infections. The findings provide valuable insights into the effectiveness and safety of PPV23 in this population, prompting further research and policy considerations to optimize vaccination strategies and enhance the well-being of HIV-infected individuals.

Date :
  1. Date Completed 2022-01-26
  2. Date Revised 2022-01-26
Further Info :

Pubmed ID

34857419

DOI: Digital Object Identifier

10.1016/j.vaccine.2021.11.058

Related Literature

Article Analysis
・Effects of pneumococcal polysaccharide vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.